Navigation Links
Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
Date:10/3/2008

Readies R & D facilities for Ap3ana, CTI's 'personalized medicine' venture

SEATTLE, Oct. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) announced today that Christina A. Waters, Ph.D., M.B.A., most recently President and COO of a Tyr Pharma and formerly Director of Scientific Development at Genomics Institute of the Novartis Research Foundation, has been named President of CTI Europe. Based in Bresso, Italy, CTI Europe currently conducts the research and development of CTI's cancer drug pipeline.

"With her specialized background in genomics, hands on experience in integrating research and development operations, and proven strategic portfolio development capabilities, Dr. Waters, a Howard Hughes Fellow, is an excellent choice to lead the Bresso unit," said James A. Bianco, M.D., CEO of CTI. "She will bring the necessary knowledge and experience in oncology to direct Bresso's world-class scientists and bridge R&D with Translational Medicine," Bianco added.

"Leading the Bresso operation is a great opportunity as it will be a key part of the foundation on which we build Ap(3)ana. This is truly the time when we will see major advancements made in health care and we intend to be at the heart of it," Dr. Waters said.

In her new role as President of CTI Europe, Dr. Waters, will accelerate the launch of Ap(3)ana, an organization that will seek to integrate new technologies in the areas of informatics, genetics, preclinical and clinical development to advance medical treatment and predictive medicine.

Ap(3)ana is expected to combine Bresso's R & D capabilities with the advanced genomic screening of CTI's Systems Medicine subsidiary, and novel computational technologies of The Translational
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
4. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
7. Former Patent Office Solicitor and Judge Joins Rothwell Figg
8. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
9. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
10. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
11. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Topical BioMedics, Inc., is celebrating ... end their suffering, restoring hope an quality of life ... only possible because of the innovative cellular biomedicines research ... a reality. , The company was founded in ... Paradise (president, chief of research, and Topricin inventor), Aurora ...
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "Global and Chinese Microcrystalline Cellulose Industry Report 2014" ... Global and Chinese Microcrystalline Cellulose Industry Report 2014 is ... of the global microcrystalline cellulose industry with a focus ... a basic overview of the industry including definitions, classifications, ...
(Date:9/22/2014)... LANSING, Mich., Sept. 22, 2014  Neogen Corporation (Nasdaq: ... for the first quarter of its 2015 fiscal year, ... increase compared to net income of $7,839,000 in the ... stock split effective Oct. 30, 2013, earnings per share ... a year ago. First quarter revenues increased ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... interesting meeting took place this past week at the University ... The focus of the meeting was an opportunity to hear ... last annual BIO meetings in different cities, as a preview ... this Olympics of Biotechnology meeting comes to Chicago in April, ...
... hit a nerve. , , I heard from a number ... 2.0 is spelled b-u-b-b-l-e, and who want none of it. As ... use a healthy dose of caution to prevent the heavy Kool-Aid ... group. , ,Indeed, in dozens of conversations with start-ups seeking a ...
... and after its recent redesign The Internal Revenue Service ... well as tweaking its search engine to hopefully make it easier ... keeping roughly the same design since mid-2002, the IRS decided to ... Among other features, the site has links to the most-requested publications ...
Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6Can we prevent Web 2.0 from being a bubble? 2Can we prevent Web 2.0 from being a bubble? 3
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... significantly less likely to report taking iron supplements before ... who are developing normally, a study by researchers with ... iron intake was associated with a five-fold greater risk ... 35 or older at the time of the child,s ... as obesity hypertension or diabetes. , The research is ...
(Date:9/21/2014)... at the University of California, San Diego, have developed ... that control the activity of genes based on sequences ... from its application to human embryonic cells in a ... 21. , "All of our cells have the same ... said John Whitaker, lead author of the report. "Skin ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
... Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the ... approved,the scheme of arrangement between Shire plc and ... which becomes effective on 23 May 2008,results in ... SHP,NASDAQ: SHPGY) becoming the new holding company for ...
... CORVALLIS, Ore. An international team of scientists surveying ... Coast of North America has discovered for the first ... miles of the shoreline, raising concern for marine ecosystems ... an Oregon State University research vessel, also discovered that ...
... called FIGLA cause premature ovarian failure in at least a ... from Baylor College of Medicine in Houston and Shandong University ... the American Journal of Human Genetics. We hope to ... genes associated with this problem to find biomarkers in blood ...
Cached Biology News:Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3Oocyte-specific gene mutations cause premature ovarian failure 2
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Biology Products: